Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Iovance (NASDAQ: IOVA) will report Q1 2026 financial results and provide corporate updates on Thursday, May 7, 2026 at 8:30 a.m. ET.

Rhea-AI Summary

Iovance (NASDAQ: IOVA) will report Q1 2026 financial results and provide corporate updates on Thursday, May 7, 2026 at 8:30 a.m. ET. The company will host a conference call and live audio webcast; an archived webcast will be available for one year.

Investors can register for the live or archived audio webcast via the provided registration link or access it in the Investors section at IR.Iovance.com.

Argus Apr 27 session

-0.29% close to close Open Argus

Details

News Market Reaction – IOVA

In the Apr 27 session, IOVA declined 0.29%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Iovance’s first quarter 2026 results and corporate update on M...

Analysis

This announcement sets the timing for Iovance’s first quarter 2026 results and corporate update on May 7, 2026 at 8:30 a.m. ET, with the webcast archived for one year. In recent quarters the company reported product revenue of about $87 million in Q4 2025 and roughly $264 million for full-year 2025 with gross margin near 50%. Investors may watch upcoming disclosures on revenue trends, margins, and cash usage when the full results are released.

Key Figures

Earnings call date: May 7, 2026 Earnings call time: 8:30 a.m. ET Webcast archive period: 1 year +5 more

Earnings call date

May 7, 2026

First quarter 2026 financial results and corporate updates

Earnings call time

8:30 a.m. ET

Start time for Q1 2026 conference call and webcast

Webcast archive period

1 year

Archived earnings webcast availability on investor website

Q4 2025 revenue

≈$87 million

Fourth-quarter 2025 product revenue

Q4 QoQ growth

≈30%

Quarter-over-quarter product revenue growth in Q4 2025

Full-year 2025 revenue

≈$264 million

2025 revenue, within $250M–$300M guidance range

2025 gross margin

≈50%

Reported gross margin for 2025

Cash balance

≈$303 million

Cash expected to fund operations into Q3 2027 (as of prior report)

Previous Earnings date Reports

1 past event · Latest: Feb 11

Same Type 1 event

1. Feb 11

   Earnings date notice

   24h Move

   -3.1%

   Set timing for Q4 and full-year 2025 earnings call and webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tumor infiltrating lymphocyte, webcast

2 terms

tumor infiltrating lymphocyte medical

"delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients"

Tumor-infiltrating lymphocyte (TIL) is an immune cell found inside a tumor that can recognize and attack cancer cells; researchers can extract and multiply these patient-derived cells to use as a personalized therapy. Investors watch TILs because therapies built from them offer a targeted, individualized approach—like retraining a patient’s own soldiers to fight a specific enemy—which can influence clinical trial outcomes, regulatory decisions, and the commercial value of biotech companies.

webcast technical

"will host a conference call and live audio webcast on Thursday, May 7, 2026"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates.

To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wmx3s4fc. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi ^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com 
650-260-7120 ext. 150

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Iovance (IOVA) report Q1 2026 results and how can investors listen?

Iovance will report results on May 7, 2026 at 8:30 a.m. ET via a conference call and live audio webcast. According to the company, investors can register for the webcast at the provided registration URL or access the archived audio in the Investors section at IR.Iovance.com.

Will the Iovance (IOVA) webcast for May 7, 2026 be available after the live event?

Yes. According to the company, the webcast will be archived and available for one year following the live event. Investors can access the archived audio through the company's Investors website without attending the live conference call.

What topics will Iovance (IOVA) cover during the May 7, 2026 corporate update?

The company will report first quarter 2026 financial results and provide corporate updates during the call. According to the company, the presentation is expected to cover financial results and broader corporate developments relevant to investors.

How do I register to listen to the Iovance (IOVA) May 7, 2026 live audio webcast?

Register via the event registration URL provided by the company to access the live or archived audio webcast. According to the company, completing registration grants access to the live stream and the archived audio hosted in the Investors section.

Where can I find the archived Iovance (IOVA) Q1 2026 webcast after May 7, 2026?

The archived webcast will be posted in the Investors section of the company's website and kept for one year. According to the company, investors can revisit the archived audio at IR.Iovance.com during that retention period.

Will Iovance (IOVA) provide a replay or transcript of the May 7, 2026 call for shareholders?

An archived audio webcast will be available for one year; the company did not specify a transcript. According to the company, the live and archived audio can be accessed via the Investors website, where additional materials may be posted.